Floatz logo

DOMPERIDONE

Parkinson's Disease

Canadian Network for Observational Drug Effect Studies, CNODESSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
73/ 100

Competitive context

256 Active assets in the Parkinson's Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Istradefylline
Georgetown University
Phase 4BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB

View all 50 →

Same molecule, other indications

DOMPERIDONE is also rated in:

relapsing-remitting multiple sclerosisDormant
B
Indicative ·
57 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
57 / 100
View asset →
Orthostatic HypotensionDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →